ProfileGDS5678 / 1422732_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 79% 79% 81% 79% 76% 77% 80% 80% 80% 80% 79% 80% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.8253982
GSM967853U87-EV human glioblastoma xenograft - Control 25.4885379
GSM967854U87-EV human glioblastoma xenograft - Control 35.4782679
GSM967855U87-EV human glioblastoma xenograft - Control 45.9928381
GSM967856U87-EV human glioblastoma xenograft - Control 55.593479
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.9139576
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.116877
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.6540280
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.6216680
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.7358480
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.6776480
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.6112179
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.692480
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.6450780